Checkpoint Therapeutics, Inc.

NasdaqCM:CKPT Lagerbericht

Marktkapitalisierung: US$356.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Checkpoint Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Für Checkpoint Therapeutics wird ein Gewinn- und Umsatzwachstum von 37.7% bzw. 35.2% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 39% pro Jahr steigen soll.

Wichtige Informationen

37.7%

Wachstumsrate der Gewinne

38.96%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.3%
Wachstumsrate der Einnahmen35.2%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert19 May 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Sep 20

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 08

Checkpoint: Strong Data, But Comes With Risks

Summary CKPT produced strong data for cosibelimab. However, data was ex-US and from an open-label trial. There's not much cash at CKPT. Checkpoint Therapeutics (CKPT) produced positive results from the registration trial of cosibelimab in skin cancer, however the stock continues to stay depressed from its November highs. What happened in November, why is it still down, and what can make it go back up again - these are the questions. The funny thing here is that nothing really happened in November. I looked at every possible source of data, and apart from a non-relevant earnings release, there doesn't seem to be any particular event or news that led to the spike and the drop around the first week of November. The only thing that came out was the earnings release, on November 4, and like I said, it contains no clues to the price volatility. I checked insider transaction data, and while the insiders here do not ever buy the stock, there are no large sales around November either. I checked another article by a fellow contributor written around that time, and apart from telling us not to worry, they do not shed much illumination on why the stock fell. There wasn't unusual volume either - a sure sign of price volatility - at that time. However, if you look at the charts vis-a-vis the earnings dates, you will see that the stock peaked exactly on earnings release, and then fell drastically. So my best guess is that investors were looking for more clarity on the cosibelimab data release in the earnings press release, which did not happen, leading to the fall. Recall that data was supposed to have been released by end-2021. Speaking of unusual volume, on January 25, ~25 million shares changed hands on that date, against an average volume of 200k odd shares. These were mostly sells. This means, funds must have offloaded their entire stakes that day, the same day when cosibelimab data came out. Such a huge sell-off must have been what kept the stock subdued despite positive trial data. So we do not see a spike even on positive data release - which should be a lesson for biotech investors who play catalyst-driven stocks. The lesson is this: it is naive to think that a catalyst alone will push a stock up. There's a lot of volatility hidden under the murky waters of biopharma investing, and therefore things aren't so predictable here. Coming to the data itself, cosibelimab is an anti-PD-L1 antibody, and it was administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). Key data were: The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4% (95% CI: 36.0, 59.1) based on independent central review of 78 patients using RECIST 1.1 criteria. The median duration of response ((DOR)) had not yet been reached at the data cut-off point (76% of responses are ongoing). Safety data across 201 patients with advanced cancers enrolled and treated in all cohorts remain consistent with those previously reported, with the majority of treatment-emergent adverse events reported as Grade 1 or 2 in severity. Besides metastatic cSCC, the molecule also had an objective response rate (ORR) of 54.8% in 31 patients with locally advanced cSCC. The company presented competitor data in these two indications. The two approved products are Libtayo and Keytruda. The ORR rates from their pivotal trials are quite similar to cosibelimab's data. However, the company has not provided granularity on complete responses besides saying that they are similar to "what's out there," according to Evaluate. 2020 data did show this to be true. Checkpoint's focus is to get into the PD-L1 market with a lower cost drug. Data is also competitive. However, how the FDA will look at it ultimately decides its fate - and they only have an open label phase 1 trial data here, that too outside the US. Recently, Eli Lilly (LLY) and EQRx (EQRX) have tried to bring Chinese PD-L1 inhibitors into the US market, however, the FDA has not been too kind, at least not with Lilly, slamming them for their single country trials. Those are risk factors for Checkpoint, however its trial, although ex-US, was not single-country, having taken place in 9 different countries including France, Spain and Australia. The company also recently wound down the CONTERNO study, a phase 3 study in lung cancer for cosibelimab, citing the Ukraine war as the reason for unsustainably longer enrollment periods. Besides cosibelimab, Checkpoint has a second asset in phase 3 trial - Olafertinib, an anti-EGFR molecule partnered with other companies in Asia. Unlike other EGFRi like Tagrisso® (osimertinib), which have safety issues like
Seeking Alpha • Aug 12

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Checkpoint Therapeutics press release (NASDAQ:CKPT): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.02M (-87.5% Y/Y) beats by $0.01M. As of June 30, 2022, Checkpoint’s cash and cash equivalents totaled $30.9 million, compared to $41.5 million at March 31, 2022 and $54.7 million at December 31, 2021, a decrease of $10.6 million for the quarter and a decrease of $23.8 million for the first half of 2022. Shares -0.79% PM.
Analyseartikel • May 18

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patients with cutaneous squamous cell carcinoma. Cosibelimab holds the potential to disrupt the $30 billion PD-(L)1 class of drugs. Cosibelimab is also being developed to treat patients with non-small cell lung cancer, with a global market that is expected to grow to $11.87 billion by 2028.
Analyseartikel • Feb 15

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 28

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Checkpoint Therapeutics recently announced Cosibelimab hit its primary endpoint with a 47.4% ORR in metastatic cSCC. The company also reported positive safety and tolerability profile. The topline results have encouraged the company to submit a BLA to the FDA later this year. In addition, the company is planning on filing for approval in the EU. If approved, Cosibelimab has a unique profile and competitive pricing that could make it a serious contender in a growing immunotherapy market. The announcement triggered a disappointing spike in the share price. I suspect the market is waiting for additional data and perhaps approval in hand before fully committing to CKPT. I believe the lackluster response to the data has produced a buying opportunity.
Seeking Alpha • Nov 26

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch in 2023. Volatility has the share price, which is making big moves in both directions as we move closer to year-end. Investors need to have a game plan. I believe the recent pullback could be a great opportunity for me to buy ahead of this incredibly potent catalyst.
Analyseartikel • Oct 30

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Jul 17

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 14

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

Checkpoint Therapeutics expects to report Cosibelimab’s top-line data in Q4 of this year. The company anticipates submitting a BLA and MMA next year with a potential launch in 2023. I have pushed CKPT aside several times, but I can no longer ignore its potential upside from Cosibelimab and its potential to disrupt a $25B+ checkpoint market. I review some of Cosibelimab’s data and match it up to some of the market’s leading PD-1 and PD-L1 agents. I reveal my investment strategy and long-term outlook.
Seeking Alpha • Jun 21

Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

The following slide deck was published by Checkpoint Therapeutics, Inc. in conjunction with this event.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CKPT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2027915577560N/A1
12/31/202618610485N/A1
12/31/2025732329N/A1
3/31/20250-57N/AN/AN/A
12/31/20240-56-31-31N/A
9/30/20240-46-31-31N/A
6/30/20240-42-34-34N/A
3/31/20240-52-40-40N/A
12/31/20230-52-48-48N/A
9/30/20230-54-56-56N/A
6/30/20230-59-53-53N/A
3/31/20230-56-52-52N/A
12/31/20220-63-58-58N/A
9/30/20220-71-52-52N/A
6/30/20220-72-47-47N/A
3/31/20220-67-41-41N/A
12/31/20210-57-26-26N/A
9/30/20210-37-22-22N/A
6/30/20210-31-20-20N/A
3/31/20210-26-17-17N/A
12/31/20201-23-17-17N/A
9/30/20201-22-16-16N/A
6/30/20201-22-15-15N/A
3/31/20202-22-18-18N/A
12/31/20192-25-21-21N/A
9/30/20195-28-24-24N/A
6/30/20194-32-27-27N/A
3/31/20194-33-29-29N/A
12/31/20184-36N/A-26N/A
9/30/20181-31N/A-22N/A
6/30/20181-27N/A-20N/A
3/31/20181-27N/A-18N/A
12/31/20172-23N/A-15N/A
9/30/20172-25N/A-15N/A
6/30/20172-24N/A-14N/A
3/31/20173-23N/A-11N/A
12/31/20163-22N/A-10N/A
9/30/20162-22N/A-7N/A
6/30/20162-21N/A-7N/A
3/31/20160-16N/A-5N/A
12/31/20151-14N/A-1N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CKPT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.9%).

Ertrag vs. Markt: CKPT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CKPT wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CKPTDie Einnahmen des Unternehmens (35.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: CKPTDie Einnahmen des Unternehmens (35.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CKPT in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2025/06/03 22:15
Aktienkurs zum Tagesende2025/05/29 00:00
Gewinne2025/03/31
Jährliche Einnahmen2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Checkpoint Therapeutics, Inc. wird von 3 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.